Gyre Therapeutics, Inc. Stock price

Equities

GYRE

US4037831033

Biotechnology & Medical Research

End-of-day quote Nasdaq 23:00:00 22/02/2024 GMT 5-day change 1st Jan Change
22.03 USD +37.69% Intraday chart for Gyre Therapeutics, Inc. +43.24% -14.25%
Dynamic Chart
1 day+37.69%
1 week+43.24%
Current month+78.09%
1 month+36.32%
3 months+36.75%
Current year-14.25%
More quotes
1 week
13.55
Extreme 13.55
24.07
1 month
10.41
Extreme 10.41
24.07
Current year
10.41
Extreme 10.41
27.45
1 year
5.88
Extreme 5.88
30.40
3 years
5.88
Extreme 5.88
30.40
5 years
5.88
Extreme 5.88
30.40
10 years
5.88
Extreme 5.88
30.40
More quotes
Gyre Therapeutics, Inc., formerly Catalyst Biosciences, Inc., is a biotechnology company. The Company is focused on organ fibrosis and inflammatory diseases. The Company is primarily focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). The Company is also advancing a diverse pipeline in China through a controlling interest in Beijing Continent, including pirfenidone, F573, F528, and F230. Pirfenidone is used for idiopathic pulmonary fibrosis and is undergoing Phase 3 trials in dermatomyositis interstitial lung disease, systemic sclerosis-associated interstitial lung disease, and pneumoconiosis, along with a Phase 1 trial in diabetic kidney disease. F573 is being investigated for acute-on-chronic liver failure, while F528 and F230 are being evaluated for chronic obstructive pulmonary disease and pulmonary arterial hypertension, respectively.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
  1. Stock
  2. Equities
  3. Stock Gyre Therapeutics, Inc. - Nasdaq
+229% on MICROSOFT CORPORATION since our purchase on January 11, 2019
Replicate our performance
fermer